{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:17:08Z","timestamp":1793456228393,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Allergic drug reaction or drug allergy is an immunologically mediated drug hypersensitivity reaction (DHR). G-protein coupled receptors (GPCRs) are common drug targets and communicate extracellular signals that initiate cellular responses. Recent evidence shows that GPCR MRGPRX2 is of major importance in IgE-independent pseudo-allergic DHRs based on the suspected interactions between many FDA-approved peptidergic compounds and MRGPRX2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Our aim was to uncover novel MRGPRX2-selective and -potent agonists as drug candidates responsible for clinical features of pseudo-allergic DHRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a primary high-throughput screening (HTS), coupled with mutagenesis targeting the MRGPRX2 N62S mutation, on a panel of 3,456 library compounds. We discovered pharmacologically active hit compounds as agonists of the MRGPRX2 protein according to high degrees of potency evaluated by the calcium response and validated by the degranulation assay. Using the molecular tool Forge, we also characterized the structure-activity relationship shared by identified hit compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The alternative allele of single nucleotide polymorphism rs10833049 (N62S) in MRGPRX2 demonstrated <jats:italic>loss-of-function<\/jats:italic> property in response to substance P and antineoplastic agent daunorubicin hydrochloride. We applied a unique assay system targeting the N62S mutation to the HTS and identified 84 MRGPRX2-selective active hit compounds representing diverse classes according to primary drug indications. The top five highly represented groups included fluoroquinolone and non-fluoroquinolone antibiotics; antidepressive\/antipsychotic; antihistaminic and antineoplastic agents. We classified hit compounds into 14 clusters representing a variety of chemical and drug classes beyond those reported, such as opioids, neuromuscular blocking agents, and fluoroquinolones. We further demonstrated MRGPRX2-dependent degranulation in the human mast cell line LAD2 cells induced by three novel agonists representing the non-fluoroquinolone antibiotics (bacitracin A), anti-allergic agents (brompheniramine maleate) and tyrosine-kinase inhibitors (imatinib mesylate).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings could facilitate the development of interventions for personalized prevention and treatment of DHRs, as well as future pharmacogenetic investigations of MRGPRX2 in relevant disease cohorts.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.997389","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:50:24Z","timestamp":1666338624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Biological screening of a unique drug library targeting MRGPRX2"],"prefix":"10.3389","volume":"13","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathachit","family":"Limjunyawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbjit","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Donald","family":"MacGlashan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jaip.2020.08.002","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: General concepts","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol In practice"},{"key":"B2","article-title":"Adverse drug reactions: types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am Family phys"},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2017.11.033","article-title":"Pharmacogenomics of GPCR drug targets","volume":"172","author":"Hauser","year":"2018","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00483-4","article-title":"A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons","volume":"106","author":"Dong","year":"2001","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jid.2020.06.030","article-title":"MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria","volume":"141","author":"Shtessel","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-neuro-083019-024537","article-title":"Neural mechanisms of itch","volume":"43","author":"Lay","year":"2020","journal-title":"Annu Rev Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cells10051033","article-title":"Unlocking the non-IgE-Mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2)","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11628","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"Navines-Ferrer","year":"2018","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/pharmacy7030097","article-title":"Quinolone allergy","volume":"7","author":"McGee","year":"2019","journal-title":"Pharmacy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2334","article-title":"In silico design of novel probes for the atypical opioid receptor MRGPRX2","volume":"13","author":"Lansu","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaci.2020.12.655","article-title":"A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice","volume":"148","author":"Wolf","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.076","article-title":"Inflamed ulcerative colitis regions associated with MRGPRX2-mediated mast cell degranulation and cell activation modules, defining a new therapeutic target","volume":"160","author":"Chen","year":"2021","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1087057114563024","article-title":"In vitro screening for drug repositioning","volume":"20","author":"Wilkinson","year":"2015","journal-title":"J biomol screening"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1087057103258285","article-title":"Improved statistical methods for hit selection in high-throughput screening","volume":"8","author":"Brideau","year":"2003","journal-title":"J biomol screening"},{"key":"B17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J biomol screening"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/ci050357s","article-title":"Molecular field extrema as descriptors of biological activity: definition and validation","volume":"46","author":"Cheeseright","year":"2006","journal-title":"J Chem Inf model"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13321-020-00445-4","article-title":"One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome","volume":"12","author":"Capecchi","year":"2020","journal-title":"J cheminformatic"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.046","article-title":"A single amino acid in MRGPRX2 necessary for binding and activation by pruritogens","volume":"140","author":"Reddy","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2020.06.004","article-title":"Advances in G protein-coupled receptor high-throughput screening","volume":"64","author":"Yasi","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1186","article-title":"Statistical practice in high-throughput screening data analysis","volume":"24","author":"Malo","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199911000-00001","article-title":"Hypersensitivity reactions to rifampin. pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions","volume":"78","author":"Martinez","year":"1999","journal-title":"Medicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12053","article-title":"Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours","volume":"13","author":"Smrkovski","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: Specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol In practice"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2019.05.006","article-title":"Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines","volume":"98","author":"Capeloa","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"B29","first-page":"54","article-title":"Nonallergic hypersensitivity to nonsteroidal antiinflammatory drugs, angiotensin-converting enzyme inhibitors, radiocontrast media, local anesthetics, volume substitutes and medications used in general anesthesia","volume":"17","author":"Jurakic Toncic","year":"2009","journal-title":"Acta dermatovenerol Croatica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000453265","article-title":"Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms","volume":"171","author":"Pichler","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/WOX.0b013e318186fb3a","article-title":"H1 antihistamines: current status and future directions","volume":"1","author":"Simons","year":"2008","journal-title":"World Allergy Organ J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jaci.2011.09.005","article-title":"Histamine and H1-antihistamines: celebrating a century of progress","volume":"128","author":"Simons","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1376-5","article-title":"Drug-induced anaphylaxis: a decade review of reporting to the Portuguese pharmacovigilance authority","volume":"69","author":"Ribeiro-Vaz","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"B34","article-title":"Urticaria caused by antihistamines: report of 5 cases","volume":"19","author":"Rodriguez del Rio","year":"2009","journal-title":"J invest allergol Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04077-y","article-title":"Structure, function and pharmacology of human itch receptor complexes","volume":"600","author":"Yang","year":"2021","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/pro.3526","article-title":"Structural biology of G protein-coupled receptor signaling complexes","volume":"28","author":"Edward Zhou","year":"2019","journal-title":"Protein Sci Publ Protein Soc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.03.029","article-title":"Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European organisation for research and treatment of cancer, the Italian sarcoma group, and the Australasian gastro-intestinal trials group (EORTC-ISG-AGITG)","volume":"42","author":"Van Glabbeke","year":"2006","journal-title":"Eur J cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S5775","article-title":"Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"4","author":"Mughal","year":"2010","journal-title":"Biol Targets Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0304","article-title":"Hypersensitivity to imatinib: Successful desensitization in a skin test-positive patient","volume":"28","author":"Penza","year":"2018","journal-title":"J invest allergol Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60016-6","article-title":"Desensitization to imatinib in patients with leukemia","volume":"97","author":"Nelson","year":"2006","journal-title":"Ann allergy Asthma Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.46747\/cfp.6706414","article-title":"Approach to allergic contact dermatitis caused by topical medicaments","volume":"67","author":"Choi","year":"2021","journal-title":"Can Family phys Medecin famille canadien"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60736-3","article-title":"Detection of IgE antibodies to bacitracin using a commercially available streptavidin-linked solid phase in a patient with anaphylaxis to triple antibiotic ointment","volume":"98","author":"Sharif","year":"2007","journal-title":"Ann allergy Asthma Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.03.025","article-title":"Anaphylaxis after application of topical bacitracin-neomycin powder","volume":"115","author":"Bommarito","year":"2015","journal-title":"Ann allergy Asthma Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89362","article-title":"Dual action of neurokinin-1 antagonists on mas-related GPCRs","volume":"1","author":"Azimi","year":"2016","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.547","article-title":"MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactions","volume":"7","author":"Grimes","year":"2019","journal-title":"Pharmacol Res perspect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:50:29Z","timestamp":1666338629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2022.997389"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.997389","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"article-number":"997389"}}